Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment

Md Raihan Chowdhury, Rahman Md Moshikur, Rie Wakabayashi, Yoshiro Tahara, Noriho Kamiya, Muhammad Moniruzzaman, Masahiro Goto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This communication reports the preliminary results on the ionic liquid (IL)-based PTX formulations developed to address the aforementioned issues. The formulations were composed of PTX/cholinium amino acid ILs/ethanol/Tween-80/water. A significant enhancement in the solubility of PTX was observed with considerable correlation with the density and viscosity of the ILs, and with the side chain of the amino acids used as anions in the ILs. Moreover, the formulations were stable for up to 3 months. The driving force for the stability of the formulation was hypothesized to be the involvement of different types of interactions between the IL and PTX. In vitro cytotoxicity and antitumor activity of the IL-based formulations were evaluated on HeLa cells. The IL vehicles without PTX were found to be less cytotoxic than Taxol, while both the IL-based PTX formulation and Taxol exhibited similar antitumor activity. Finally, in vitro hypersensitivity reactions were evaluated on THP-1 cells and found to be significantly lower with the IL-based formulation than Taxol. This study demonstrated that specially designed ILs could provide a potentially safer alternative to Cremophor EL as an effective PTX formulation for cancer treatment giving fewer hypersensitivity reactions.

Original languageEnglish
Pages (from-to)2484-2488
Number of pages5
JournalMolecular pharmaceutics
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 4 2018

Fingerprint

Ionic Liquids
Paclitaxel
Neoplasms
Therapeutics
Hypersensitivity
Amino Acids
Polysorbates
HeLa Cells
Viscosity
Intravenous Administration
Solubility
Anions

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Ionic-Liquid-Based Paclitaxel Preparation : A New Potential Formulation for Cancer Treatment. / Chowdhury, Md Raihan; Moshikur, Rahman Md; Wakabayashi, Rie; Tahara, Yoshiro; Kamiya, Noriho; Moniruzzaman, Muhammad; Goto, Masahiro.

In: Molecular pharmaceutics, Vol. 15, No. 6, 04.06.2018, p. 2484-2488.

Research output: Contribution to journalArticle

Chowdhury, Md Raihan ; Moshikur, Rahman Md ; Wakabayashi, Rie ; Tahara, Yoshiro ; Kamiya, Noriho ; Moniruzzaman, Muhammad ; Goto, Masahiro. / Ionic-Liquid-Based Paclitaxel Preparation : A New Potential Formulation for Cancer Treatment. In: Molecular pharmaceutics. 2018 ; Vol. 15, No. 6. pp. 2484-2488.
@article{f0a1938c11ff46b49993cbe4422faf8c,
title = "Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment",
abstract = "Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This communication reports the preliminary results on the ionic liquid (IL)-based PTX formulations developed to address the aforementioned issues. The formulations were composed of PTX/cholinium amino acid ILs/ethanol/Tween-80/water. A significant enhancement in the solubility of PTX was observed with considerable correlation with the density and viscosity of the ILs, and with the side chain of the amino acids used as anions in the ILs. Moreover, the formulations were stable for up to 3 months. The driving force for the stability of the formulation was hypothesized to be the involvement of different types of interactions between the IL and PTX. In vitro cytotoxicity and antitumor activity of the IL-based formulations were evaluated on HeLa cells. The IL vehicles without PTX were found to be less cytotoxic than Taxol, while both the IL-based PTX formulation and Taxol exhibited similar antitumor activity. Finally, in vitro hypersensitivity reactions were evaluated on THP-1 cells and found to be significantly lower with the IL-based formulation than Taxol. This study demonstrated that specially designed ILs could provide a potentially safer alternative to Cremophor EL as an effective PTX formulation for cancer treatment giving fewer hypersensitivity reactions.",
author = "Chowdhury, {Md Raihan} and Moshikur, {Rahman Md} and Rie Wakabayashi and Yoshiro Tahara and Noriho Kamiya and Muhammad Moniruzzaman and Masahiro Goto",
year = "2018",
month = "6",
day = "4",
doi = "10.1021/acs.molpharmaceut.8b00305",
language = "English",
volume = "15",
pages = "2484--2488",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Ionic-Liquid-Based Paclitaxel Preparation

T2 - A New Potential Formulation for Cancer Treatment

AU - Chowdhury, Md Raihan

AU - Moshikur, Rahman Md

AU - Wakabayashi, Rie

AU - Tahara, Yoshiro

AU - Kamiya, Noriho

AU - Moniruzzaman, Muhammad

AU - Goto, Masahiro

PY - 2018/6/4

Y1 - 2018/6/4

N2 - Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This communication reports the preliminary results on the ionic liquid (IL)-based PTX formulations developed to address the aforementioned issues. The formulations were composed of PTX/cholinium amino acid ILs/ethanol/Tween-80/water. A significant enhancement in the solubility of PTX was observed with considerable correlation with the density and viscosity of the ILs, and with the side chain of the amino acids used as anions in the ILs. Moreover, the formulations were stable for up to 3 months. The driving force for the stability of the formulation was hypothesized to be the involvement of different types of interactions between the IL and PTX. In vitro cytotoxicity and antitumor activity of the IL-based formulations were evaluated on HeLa cells. The IL vehicles without PTX were found to be less cytotoxic than Taxol, while both the IL-based PTX formulation and Taxol exhibited similar antitumor activity. Finally, in vitro hypersensitivity reactions were evaluated on THP-1 cells and found to be significantly lower with the IL-based formulation than Taxol. This study demonstrated that specially designed ILs could provide a potentially safer alternative to Cremophor EL as an effective PTX formulation for cancer treatment giving fewer hypersensitivity reactions.

AB - Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This communication reports the preliminary results on the ionic liquid (IL)-based PTX formulations developed to address the aforementioned issues. The formulations were composed of PTX/cholinium amino acid ILs/ethanol/Tween-80/water. A significant enhancement in the solubility of PTX was observed with considerable correlation with the density and viscosity of the ILs, and with the side chain of the amino acids used as anions in the ILs. Moreover, the formulations were stable for up to 3 months. The driving force for the stability of the formulation was hypothesized to be the involvement of different types of interactions between the IL and PTX. In vitro cytotoxicity and antitumor activity of the IL-based formulations were evaluated on HeLa cells. The IL vehicles without PTX were found to be less cytotoxic than Taxol, while both the IL-based PTX formulation and Taxol exhibited similar antitumor activity. Finally, in vitro hypersensitivity reactions were evaluated on THP-1 cells and found to be significantly lower with the IL-based formulation than Taxol. This study demonstrated that specially designed ILs could provide a potentially safer alternative to Cremophor EL as an effective PTX formulation for cancer treatment giving fewer hypersensitivity reactions.

UR - http://www.scopus.com/inward/record.url?scp=85047431364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047431364&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.8b00305

DO - 10.1021/acs.molpharmaceut.8b00305

M3 - Article

C2 - 29762034

AN - SCOPUS:85047431364

VL - 15

SP - 2484

EP - 2488

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 6

ER -